Explore more publications!

Press Releases

Why Telemedicine Needs Medical Governance, Not Just Technology
Plutus Health CEO Thomas John to Speak at BHASe Summit 2026 on Sustainable Revenue for Behavioral Health
Washington Update covers Rural Health Transformation Fund, affordability
Mentavi Health to Present Adult ADHD Diagnostic Evaluation Validation Data at National Psychopharmacology Update 2026
Wattanosoth Cancer Hospital engages Mayo Clinic Global Consulting to advance healthcare excellence in cancer care
Valentine’s Day 2026 Wellness Gift Report: Hume Health Body Pod Highlights Growing Interest in Metabolic Insight at Home
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
Valentine’s Day 2026 Wellness Gift Report: Hume Band Highlights Long-Term Health Tracking and Metabolic Awareness
Charcuterie and health: what the facts really say (not the shortcuts)
Valentine’s Day 2026 Gift Trends Report: Health Technology Emerges as a Leading Choice for Long-Term Wellness
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
Vidac Pharma Initiates In Vivo Pre-Clinical Program in Psoriasis, Expanding Its HK2/VDAC Platform Beyond Oncology
OMICS Precision Health Launches a Healthspan Clinic in Dubai in Collaboration with Cedars-Sinai
La Selva Eco-Lodge & Retreat by GET Delivers Medical Support and Essential Supplies to Children in Ecuador’s Amazon Community of El Pilche
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
Native Sons of the Golden West Present $75,000 Donation to Sutter Health Medical Center
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Ardent Health Corporation Securities Fraud Class Action Result of Undisclosed Collections Problems and 33% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
PharmAla Announces Changes to Board of Directors

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions